Zobrazeno 1 - 10
of 68
pro vyhledávání: '"J W, Athens"'
Autor:
J. W. Athens, Homer R. Warner
Publikováno v:
Annals of the New York Academy of Sciences. 113:523-536
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa27d815e3b10e31fe804649f9a978e0
https://doi.org/10.1111/j.1749-6632.1964.tb40689.x
https://doi.org/10.1111/j.1749-6632.1964.tb40689.x
Publikováno v:
Annals of the New York Academy of Sciences. 113:963-967
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b767d193d63d05ba835d3df8037b941
https://doi.org/10.1111/j.1749-6632.1964.tb40716.x
https://doi.org/10.1111/j.1749-6632.1964.tb40716.x
Autor:
Saul E. Rivkin, C. Kent Osborne, John J. Costanzi, J. W. Athens, Danika Lew, Clarence B. Vaughn, Stephanie J. Green, Silvana Martino
Publikováno v:
Cancer. 97(1)
BACKGROUND Adjuvant combination chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil plus vincristine and prednisone (CMFVP) was compared with single-agent L-phenylalanine mustard (L-PAM) for the treatment of patients with axillary ly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d5bd7b848adefd39aff8c9777195e87
https://pubmed.ncbi.nlm.nih.gov/12491501
https://pubmed.ncbi.nlm.nih.gov/12491501
Publikováno v:
Investigational new drugs. 11(2-3)
Fifty-eight evaluable patients with acute leukemia were treated with Mitoxantrone (DHAD) according to two schedules: 14 mg/M2 as a single I.V. pulse dose administered three-week intervals, and 4 mg/M2/day for five days every three weeks. Six of 58 pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4488048679aed4b8cdd49672274997a0
https://pubmed.ncbi.nlm.nih.gov/8262731
https://pubmed.ncbi.nlm.nih.gov/8262731
Autor:
F S, Morrison, K J, Kopecky, D R, Head, J W, Athens, S P, Balcerzak, C, Gumbart, L, Dabich, J J, Costanzi, C A, Coltman, J H, Saiki
Publikováno v:
Leukemia. 6(7)
Between August 1978 and September 1982, 642 patients with newly diagnosed acute myelogenous leukemia (AML) were entered onto a Southwest Oncology Group Study which addressed four questions. (i) What is the comparative utility of rubidazone versus adr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::33648a913488402e7fbea132bf5523f3
https://pubmed.ncbi.nlm.nih.gov/1625490
https://pubmed.ncbi.nlm.nih.gov/1625490
Autor:
Thomas R. Maloney, Mary A. Foulkes, William S. Fletcher, Barth Hoogstraten, J. J. Costanzi, Nazli Gad-el-Mawla, Clarence B. Vaughn, Bill L. Tranum, J. W. Athens
Publikováno v:
Cancer. 54:2248-2256
The Southwest Oncology Group has completed a study of 213 women with the first recurrence of breast cancer. Eligibility included a radical or modified radical mastectomy for cure and recurrence which had received no other form of therapy. Patients we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68eb3932641abd66b821325e9c5e984f
https://doi.org/10.1002/1097-0142(19841115)54:10<2248::aid-cncr2820541031>3.0.co
https://doi.org/10.1002/1097-0142(19841115)54:10<2248::aid-cncr2820541031>3.0.co
Autor:
Glucksberg H, Thomas Maloney, Bill L. Tranum, Joseph D. McCracken, Shelley L. Rasmussen, J. W. Athens, B. Hoogstraten, Nazli Gad-el-Mawla, Saul E. Rivkin, Clarence B. Vaughn, John J. Costanzi
Publikováno v:
Cancer. 50:423-434
The Southwest Oncology Group in a prospective randomized study compared one year of adjuvant combination chemotherapy with continuous CMFVP to two years of intermittent L-PAM in women with operable breast cancer with histologically positive axillary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::172fad6dc9b76712cf5bc360eb318b00
https://doi.org/10.1002/1097-0142(19820801)50:3<423::aid-cncr2820500307>3.0.co
https://doi.org/10.1002/1097-0142(19820801)50:3<423::aid-cncr2820500307>3.0.co
Autor:
Mary Foulkes, Frank E. Smith, Lawrence H. Baker, Nazil Gad-el-Mawla, Bill L. Tranum, Frank J. Panettiere, J. W. Athens
Publikováno v:
Investigational New Drugs. 1:315-319
The SWOG carried out a Phase II evaluation of rubidazone in patients with advanced breast cancer. Good risk patients were given rubidazone 150 mg/m2 IV every three weeks. Poor risk patients were given a 25% dose reduction at the start of treatment. R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21a7b26f2a17809b5db4b266194be181
https://doi.org/10.1007/bf00177415
https://doi.org/10.1007/bf00177415
Autor:
J. W. Athens, Mary A. Foulkes, Robert M. O'Bryan, Saul E. Rivkin, J. J. Costanzi, Ronald L. Stephens, Glucksberg H, William A. Knight
Publikováno v:
Breast Cancer Research and Treatment. 3:S27-S33
The Southwest Oncology Group in a prospective randomized study compared one year of adjuvant combination chemotherapy with continuous CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone) to two years of intermittent L-p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57c63828da9301ebb02455a5d5fa8f04
https://doi.org/10.1007/bf01855124
https://doi.org/10.1007/bf01855124
Publikováno v:
Experimental Biology and Medicine. 115:792-796
SummaryThis study was designed to determine whether inflammatory granulocytes are derived solely from the blood or from a hypothetical extramedullary tissue pool of granulocytes, in addition to the blood. Blood granulocytes were labeled in vitro with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8960f363d4b574cb3ec804696d5bbcbd
https://doi.org/10.3181/00379727-115-29040
https://doi.org/10.3181/00379727-115-29040